ACR204 Preview Podcast (11.15.2024)

Jack Cush, MD

Nov 15, 2024 8:00 am

ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.

Previews:

Abstract Number: 2527 Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: (DAHLIAS study). Phase 2 study of adults with moderately-to-severely active primary Sjogrens (163 pts) Treated with either placebo or nipocalimab. Nipocalimab led to significant improvement in ESSDAI at W24, and was well-tolerated.
Abstract Number: 0989 Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials (RCTs) and long-term extension (LTE) studies of JAKi and TNFi, in adults with rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) TNFi was associated with a significantly lower risk of malignancy excluding NMSC when compared with both JAKi and placebo. The risk of malignancy was similar between JAKi and placebo.
Abstract Number: L16 Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3. DAP vs PBO x 48 weeks in patients (pts) with moderate-to-severe SLE. The primary endpoint (BICLA) at wk 48 was better with DAP 49.5% vs 34.6% PBO. DAP patients also had less severe BILAG flares, but had more opportunistic infections (2.8% vs 0.9%).
Abstract Number: 1315 From Presentation to Publication: Tracking the Publication Rate of Abstracts Presented at American College of Rheumatology Convergence Conference in the Years 2015 and 2018 ACR Convergence abstracts from 2015 and 2018 studied looking at full paper publication. 5890 were analyzed. Overall, 56% were published as full articles. Specifically, 1658 abstracts (55.32%) from 2015 and 1625 (56.17%) from 2018 were successfully published within 9 years and 6 years, respectively. Plenary presentations, totaling 28 (11 in 2015 and 17 in 2018), exhibited the highest publication rates: 81.81% in 2015 and 94.11% in 2018.
Abstract Number: 0458 Long-term outcomes in seronegative rheumatoid arthritis . 176 patients (68% female); median of 11.8 y follow-up. 10-y cumulative incidence of change in diagnosis: 15.1%. Diagnoses changed to : Spondyloarthropathy (11), seropositive RA (6), OA (5), crystalline arthritis (3), CTD (3), infection related arthropathy (1), paraneoplastic arthropathy (1), remitting seronegative symmetrical synovitis with pitting edema (1) and sarcoidosis (1). 10-y cumulative incidence of DFR was 26.9% and initiation of a b/tsDMARD was 18.9%.

Recommended Sessions to attend

Saturday November 16

7:45am - 8:45am Year IN review Sat, Nov 16 Hall E
- Michael Pillinger NYU and Louis Bridges HSS
915 – 1045 AM Plenary Session
1PM FDA update on Safety issues in Rheum
230PM Curbside Consults

Sunday November 17^th

9AM Plenary
1030AM Klemper Lecture Rare Autoinflammatory Diseases Raphaela Goldbach-Mansky, MD
1PM Synovial Fibroblast in Rheumatoid Arthritis: Searching for Targetable Mechanism- Nunzio Bottini, MD, PhD
1pm Knowledge Bowl Final Round
330PM GREAT DEBATE MCTD – is it just letters?
Lisa Christopher-Stine, MD, MPH
Peter Izmirly, MD

Monday November 18th